ClinicalTrials.gg
CompletedNCT00325403Updated Jan 3, 2024Results posted

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Oral treprostinil (UT-15C) Sustained Release Tablets and Placebo in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 77 sites in 13 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-03.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
5th of 44
349 · median 32
Started
2006
with 1 other
Phase 3
14 of 44
1 open now
Registered
3rd of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12.

Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary Arterial Hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

This study's enrollment of 349 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 12 and 75 years of age, inclusive.
  • Body weight at least 40 kg with a \< 45
  • PAH that is either idiopathic/heritable; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with .
  • Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.
  • Baseline 6-minute walk distance between 200 and 425 meters, inclusive.
  • Reliable and cooperative with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Nursing or pregnant.
  • Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or prostacyclin within 30 days of Baseline.
  • PAH due to conditions other than noted in the above inclusion criteria.
  • History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
  • Use of an drug within 30 days of Baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
349 participants (actual)

Study arms

  • Active comparator
    UT-15C (oral treprositnil)

    Subjects receive UT-15C (oral treprostinil) twice daily.

    Drug: Oral treprostinil (UT-15C) Sustained Release Tablets

  • Placebo comparator
    Placebo

    Subjects receive placebo (sugar pill) twice daily.

    Other: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

    Time frame: Baseline and Week 11

  2. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

    Time frame: Baseline and Week 8

  3. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

    Time frame: Baseline and Week 4

  4. Clinical Worsening Assessment

    Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)

    Time frame: Baseline and Week 12

  5. World Health Organization Functional Classification for PAH

    Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

    Time frame: Baseline and Week 12

  6. Borg Dyspnea Score

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

    Time frame: Baseline and Week 12

  7. Dyspnea-Fatigue Index

    The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

    Time frame: Baseline and Week 12

  8. Symptoms of PAH

    Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 12. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom.

    Time frame: Baseline and Week 12

08

Results

Posted Mar 18, 2013

Participant flow

349 subjects participated in the study from 24 October 2006 to 29 April 2011 at 52 of 77 sites across the United States, Puerto Rico, Canada, Europe, Israel, India, Mexico, and China. The primary endpoint was analyzed using the primary analysis population which included 228 subjects who had access to 0.25 mg tablets at the time of randomization.

Participant flow — Overall Study
MilestonePlaceboUT-15C (Oral Treprostinil)
Started116233
Completed98182
Not completed1851

Outcome measures

PrimarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline339 (282 to 381)350 (283 to 386)
6MWD at Week 12343 (246 to 403)370 (300 to 418)
Change in 6MWD from Baseline to Week 12-5 (-41 to 49)25 (-16 to 63)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0125 (P-Value) · Hodges-lehmann (h-l): 23 · 95% CI 4 to 41
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 11
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline339 (282 to 381)350 (283 to 386)
6MWD at Week 11335 (254 to 400)350 (290 to 400)
Change in 6MWD from Baseline to Week 110 (-54 to 36)8 (-25 to 50)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0653 · Hodges-lehmann (h-l): 13 · 95% CI -2 to 33
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 8
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline339 (282 to 381)350 (283 to 386)
6MWD at Week 8347 (240 to 398)355 (300 to 408)
Change in 6MWD from Baseline to Week 80 (-36 to 35)17 (-15 to 54)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0307 · Hodges-lehmann (h-l): 17 · 95% CI 1 to 33
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 4
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline339 (282 to 381)350 (283 to 386)
6MWD at Week 4350 (254 to 387)360 (285 to 400)
Change in 6MWD from Baseline to Week 40 (-28 to 17)7 (-15 to 42)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0518 · Hodges-lehmann (h-l): 12 · 95% CI 0 to 24
SecondaryClinical Worsening Assessment

Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Clinical Worsening Assessment
participantsPlaceboUT-15C (Oral Treprostinil)
Clinical Worsening Assessment815
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · Fisher Exact · p = 1.000
SecondaryWorld Health Organization Functional Classification for PAH

Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

Time frame:
Baseline and Week 12
Reported as:
Number · participants
World Health Organization Functional Classification for PAH
participantsPlaceboUT-15C (Oral Treprostinil)
WHO Class I12
WHO Class II2959
WHO Class III3875
WHO Class IV915
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · Wilcoxon rank sum test · p = 0.7380 (In cases where the "value corresponding to overall poorest relative change" was imputed for walk distance, a value of "IV" was used for the WHO functional classification for PAH.) · Hodges-lehmann (h-l): 0 · 95% CI 0 to 0The values for the estimated parameter and 95% confidence interval were calculated.
SecondaryBorg Dyspnea Score

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

Time frame:
Baseline and Week 12
Reported as:
Median · units on a scale
Borg Dyspnea Score
units on a scalePlaceboUT-15C (Oral Treprostinil)
Borg dyspnea score at Baseline3 (2 to 6)3 (2 to 4)
Borg dyspnea score at Week 123 (2 to 5)3 (1 to 5)
Change in Borg dyspnea score from Baseline to Wk120 (-1 to 1)0 (-1 to 1)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · Wilcoxon rank-sum test · p = 0.4887 · Hodges-lehmann (h-l): 0 · 95% CI -1 to 0
SecondaryDyspnea-Fatigue Index

The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Dyspnea-Fatigue Index
units on a scalePlaceboUT-15C (Oral Treprostinil)
Dyspnea-fatigue index at Baseline5.8 ± 2.46.2 ± 2.1
Dyspnea-fatigue index at Week 125.5 ± 2.95.9 ± 2.8
Change in dyspnea-fatigue index from BL to Wk 12-0.3 ± 2.5-0.3 ± 2.4
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · Wilcoxon sum-rank test · p = 0.6116 · Hodges-lehmann (h-l): 0 · 95% CI 0 to 1
SecondarySymptoms of PAH

Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 12. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Symptoms of PAH
units on a scalePlaceboUT-15C (Oral Treprostinil)
Change in fatigue symptoms0.1 ± 1.00.0 ± 1.0
Change in dyspnea symptoms-0.1 ± 0.9-0.2 ± 0.9
Change in edema symptoms0.3 ± 1.00.2 ± 1.1
Change in dizziness symptoms0.0 ± 1.00.3 ± 1.0
Change in syncope symptoms0.3 ± 1.00.3 ± 0.9
Change in chest pain symptoms0.1 ± 0.90.2 ± 1.0
Change in orthopnea symptoms0.2 ± 0.90.2 ± 1.0
Post-hocSix Minute Walk Distance by Baseline WHO Functional Classification III or IV

Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Six Minute Walk Distance by Baseline WHO Functional Classification III or IV
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline333.5 (269 to 382.5)330 (265 to 378)
6MWD at Week 12316.5 (231.5 to 385)354 (265 to 400)
Change in 6MWD from Baseline to Week 12-8.5 (-50.5 to 40)20.5 (-20 to 63)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0326 · Hodges-lehmann (h-l): 26 · 95% CI 1 to 49
Post-hocSix Minute Walk Distance by Baseline WHO Functional Classification: I or II

Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Six Minute Walk Distance by Baseline WHO Functional Classification: I or II
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline370 (297 to 378)366 (315 to 390)
6MWD at Week 12379 (274 to 429)391 (348 to 431)
Change in 6MWD from Baseline to Week 1218 (-30 to 55)27 (-5 to 67)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.2275 · Hodges-lehmann (h-l): 16.0 · 95% CI -15 to 47
Post-hocSix Minute Walk Distance (6MWD) by PAH Etiology: Idiopathic or Heritable PAH

Exploratory efficacy analyses were to determine the effect of PAH etiology (idiopathic/heritable, associated with collagen vascular disease, and other etiologies) on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by PAH Etiology: Idiopathic or Heritable PAH
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline332.5 (260 to 379)346 (281 to 390)
6MWD at Week 12310.5 (242.5 to 380)380 (304 to 420)
Change in 6MWD from BL to Wk 12-7.5 (-50.5 to 42)25 (-13 to 67)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0024 · Hodges-lehmann (h-l): 32 · 95% CI 10 to 55
Post-hocSix Minute Walk Distance (6MWD) for the Entire Study Population

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data collected from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Wk 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference i

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) for the Entire Study Population
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline338.5 (265.5 to 383.5)347 (288 to 387)
6MWD at Week 12329.5 (231.5 to 397.5)370 (304 to 420)
Change in 6MWD from Baseline to Week 120 (-46 to 40)25 (-12 to 63)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0001 · Hodges-lehmann (h-l): 25.5 · 95% CI 10 to 41
Post-hocSix Minute Walk Distance (6MWD) for the Entire Study Population

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at the time of randomization. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 11
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) for the Entire Study Population
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline338.5 (265.5 to 383.5)347 (288 to 387)
6MWD at Week 11326.5 (206 to 398)351 (303 to 403)
Change in 6MWD from Baseline to Week 11-2 (-58.5 to 36)6 (-18 to 48)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0025 · Hodges-lehmann (h-l): 17 · 95% CI 3 to 33
Post-hocSix Minute Walk Distance (6MWD) for the Entire Study Population

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 8
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) for the Entire Study Population
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline338.5 (265.5 to 383.5)347 (288 to 387)
6MWD at Week 8339.5 (227 to 392)360 (300 to 411)
Change in 6MWD from Baseline to Week 81.0 (-38.5 to 34.5)17.0 (-13 to 54)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0008 · Hodges-lehmann (h-l): 20 · 95% CI 7 to 34
Post-hocSix Minute Walk Distance (6MWD) for the Entire Study Population

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.

Time frame:
Baseline and Week 4
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) for the Entire Study Population
metersPlaceboUT-15C (Oral Treprostinil)
6MWD at Baseline338.5 (265.5 to 383.5)347 (288 to 387)
6MWD at Week 4339.5 (251 to 387)358 (288 to 403.2)
Change in 6MWD from Baseline to Week 4-4 (-31.5 to 20)7 (-13 to 42)
Statistical analysis
  • Placebo vs UT-15C (Oral Treprostinil) · ANCOVA · p = 0.0025 · Hodges-lehmann (h-l): 14 · 95% CI 3.9 to 25

Adverse events

Collected over Adverse events were recorded throughout the 12 week study which was conducted between October 2006 and April 2011.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo6/77 (7.8%)15/77 (19.5%)68/77 (88.3%)
UT-15C (Oral Treprostinil)9/151 (6%)27/151 (17.9%)138/151 (91.4%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlaceboUT-15C (Oral Treprostinil)
right ventricular failureCardiac disorders3/7710/151
pulmonary hypertensionCardiac disorders4/773/151
pneumoniaRespiratory, thoracic and mediastinal disorders3/771/151
deathGeneral disorders2/772/151
chest painMusculoskeletal and connective tissue disorders1/772/151
pulmonary embolismRespiratory, thoracic and mediastinal disorders0/772/151
hemoptysisRespiratory, thoracic and mediastinal disorders1/771/151
cardio-respiratory arrestCardiac disorders1/770/151
circulatory collapseCardiac disorders1/770/151
collagen-vascular diseaseVascular disorders1/770/151
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlaceboUT-15C (Oral Treprostinil)
headacheNervous system disorders15/7795/151
diarrheaGastrointestinal disorders12/7746/151
nauseaGastrointestinal disorders14/7745/151
vomitingGastrointestinal disorders12/7726/151
flushingVascular disorders5/7723/151
dizzinessGeneral disorders11/7717/151
Pain in extremityMusculoskeletal and connective tissue disorders6/7721/151
coughRespiratory, thoracic and mediastinal disorders9/7714/151
pain in jawMusculoskeletal and connective tissue disorders3/7717/151
pyrexiaInfections and infestations8/777/151

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboUT-15C (Oral Treprostinil)Total
<=18 years1910
Between 18 and 65 years69141210
>=65 years718
Age, Continuous
Age, Continuous(years)PlaceboUT-15C (Oral Treprostinil)Total
Mean42.5 ± 13.537.8 ± 13.539.4 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUT-15C (Oral Treprostinil)Total
Female58108166
Male194362
PAH Etiology
PAH Etiology(participants)PlaceboUT-15C (Oral Treprostinil)Total
Idiopathic or heritable PAH56114170
PAH associated w collagen vascular disease172643
PAH associated w repaired congenital heart defect31013
PAH associated w HIV infection112
Baseline Six Minute Walk Distance
Baseline Six Minute Walk Distance(meters)PlaceboUT-15C (Oral Treprostinil)Total
Mean327.6 ± 70.7331.3 ± 64.9330.0 ± 66.8
WHO Functional Classification
WHO Functional Classification(participants)PlaceboUT-15C (Oral Treprostinil)Total
WHO Class I112
WHO Class II245276
WHO Class III5298150
09

Study locations

77 sites
  • University of Alabama-Birmingham
    Birmingham, Alabama, United States
  • Arizona Pulmonary Specialist
    Phoenix, Arizona, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona, United States
  • University of California, San Francisco-Fresno
    Fresno, California, United States
  • West Los Angeles VA Healthcare Center
    Los Angeles, California, United States
  • UC Davis Medical Center
    Sacramento, California, United States
  • Harbor-UCLA Medical Center
    Torrance, California, United States
  • University of Colorado Health Science Center
    Aurora, Colorado, United States
  • University of Florida - Shands Hospital
    Jacksonville, Florida, United States
  • Cleveland Clinic Florida
    Weston, Florida, United States
  • Emory University Hospital
    Atlanta, Georgia, United States
  • University of Chicago Hospitals
    Chicago, Illinois, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana, United States
  • Maine Medical Center
    Portland, Maine, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts, United States
  • Tufts Medical Center
    Boston, Massachusetts, United States
  • University of Michigan
    Ann Arbor, Michigan, United States
  • Mayo Clinic
    Rochester, Minnesota, United States
  • Washington University Hospital
    Saint Louis, Missouri, United States
  • Nebraska Medical Center
    Omaha, Nebraska, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey, United States
  • Winthrop University Hospital
    Mineola, New York, United States
  • Columbia Presbyterian Medical Center
    New York, New York, United States
  • Mary M Parkes Center for Asthma, Allergy and Pulmonary Care - University of Rochester
    Rochester, New York, United States
  • The Lindner Center
    Cincinnati, Ohio, United States
  • University of Cincinnati
    Cincinnati, Ohio, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio, United States
  • Ohio State University
    Columbus, Ohio, United States
  • Legacy Clinic Northwest
    Portland, Oregon, United States
  • Oregon Health and Science University
    Portland, Oregon, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States
  • Medical University of South Carolina
    Charleston, South Carolina, United States
  • University of Texas Southwestern
    Dallas, Texas, United States
  • Baylor College of Medicine, Pulmonary & Critical Care
    Houston, Texas, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia, United States
  • University of Washington Medical Center
    Seattle, Washington, United States
  • Heart Care Associates
    Milwaukee, Wisconsin, United States
  • Universitaet Wien
    Wien, Austria
  • Hospital Erasme
    Brussels, Belgium
  • University Hospital Gasthuisberg
    Leuven, Belgium
  • Peter Lougheed Centre
    Calgary, Alberta, Canada
  • London Health Science Centre
    London, Ontario, Canada
  • SMBD Jewish General Hospital
    Montreal, Quebec, Canada
  • Beijing Shijitan Hospital
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Shanghai Pulmonary Hospital
    Shanghai, China
  • Hospital Antoine Beclere
    Clamart, France
  • PRIME Hospitals
    Hyderbad, Andhra Pradesh, India
  • Care Institute of Medical Science
    Ahmedabad, Gujarat, India
  • Lifecare Institute of Medical Sciences & Research
    Ahmedabad, Gujarat, India
  • Narayana Hrudayalaya Institute of Medical Sciences
    Bangalore, Karnataka, India
  • Asian Heart Institute and Research Centre
    Parel Mumbai, Maharashtra, India
  • Poona Hospital and Research Centre
    Pune, Maharashtra, India
  • Sri Ramachandra Medical College
    Chennai, Tamil Nadu, India
  • G. Kuppuswamy Naidu Memorial Hospital
    Coimbatore, Tamil Nadu, India
  • K. S. Hospital
    Chennai, Tamil Nadu, India
  • Sir Ganga Ram Hospital
    New Delhi, India
  • Ruby Hall Clinic
    Pune, India
  • Care Hospital
    Visakhapatnam, Andra Pradesh, India
  • Hadassah Ein-Kerem Medical Center
    Jerusalem, Israel
  • Rabin Medical Center
    Petach Tikva, Israel
  • Tel Hashomer Medical Center
    Ramat Gan, Israel
  • Universita degli Studi Bologna
    Bologna, Italy
  • Instituto Nacional de Cardiologia
    Mexico City, DF, Mexico
  • Hospital Universitario UANL
    Monterrey, NL, Mexico
  • Unidad de Investigacion Clinica en Medicina (UDICEM)
    Monterrey, Mexico
  • VU Medisch Centrum (VUCM)
    Amsterdam, Netherlands
  • Krakowski Szpital Specjalistyczny im. (Kraków Specialist Hospital)
    Kraków, Poland
  • National Tuberculosis and Lung Disease Research Institute
    Warsaw, Poland
  • Wojewódzki Szpital Specjalistyczny we Wroclawiu (Provincial Specialist Hospital in Wrocław)
    Wroclaw, Poland
  • Auxilio Mutuo Hospital
    Guaynabo, Puerto Rico
10

References and documents

Publications

  • Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 5;127(5):624-33. doi: 10.1161/CIRCULATIONAHA.112.124388. Epub 2013 Jan 10. PubMed 23307827 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2006
First posted
May 12, 2006
Start
Oct 2006
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Mar 18, 2013
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00325403
Responsible party
Sponsor
First posted
May 12, 2006
Start date
Oct 2006
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Mar 18, 2013
Last update
Jan 3, 2024

Study contacts

Kevin Laliberte, PharmD
study director · United Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion